Parabilis filed for an IPO to fund development of its Wnt/β-catenin pathway inhibitor zolucatetide for desmoid tumors, shortly after inking a research collaboration with Regeneron. The IPO filing targets a $100 million raise in the near term, with proceeds aimed at advancing a Phase 3 desmoid study and continuing earlier clinical programs. In early-stage data cited in the filing, Parabilis reported tumor reductions in 100% of evaluable patients and a 74% objective response rate among those with at least two post-baseline scans. The FDA granted fast track designation for desmoid tumors after that dataset. The Regeneron partnership adds a separate cash engine—an upfront payment plus an equity investment—structured around Antibody-Helicon Conjugates (AHCs) and Helicon peptides designed to reach intracellular targets. Parabilis is positioning its public market debut as a continuation of rapid internal execution after a prolonged IPO downturn.